炬光科技(688167.SH):Pixeline是公司在全球獨家的技術,客户是美國一家公司
格隆匯7月17日丨有投資者向炬光科技(688167.SH)提問,“公司的3D打印技術pixeline是否是國內獨一份?下游是否有客户合作使用該技術?”
炬光科技回覆稱,公司在投股書曾披露“公司開發的超高速像素控制3D打印線光斑系統(Pixeline)使打印速度提高至當前點光源打印速度的上百倍,克服了製造效率低、成本高等問題,成為具有突破性創新的一代3D打印技術”。Pixeline是公司在全球獨家的技術,公司的客户是美國一家公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.